First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial
Revolution Medicines has dosed the first subject in the Phase III RASolve 301 trial with the RAS (ON) multi-selective inhibitor,…
News
ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data
Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy
Nuvig Therapeutics begins dosing in trial of NVG-2089 for CIDP
Examining shifts in clinical trial outsourcing
BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug
GSK to spend $2bn on Phase III liver disease drug acquisition
Roche reports final overall survival outcomes from breast cancer treatment trial
